ATE364396T1 - Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern - Google Patents
Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpernInfo
- Publication number
- ATE364396T1 ATE364396T1 AT01911971T AT01911971T ATE364396T1 AT E364396 T1 ATE364396 T1 AT E364396T1 AT 01911971 T AT01911971 T AT 01911971T AT 01911971 T AT01911971 T AT 01911971T AT E364396 T1 ATE364396 T1 AT E364396T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- polyenes
- fungal infection
- synthesis inhibitors
- beta glucan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008305.5A GB0008305D0 (en) | 2000-04-06 | 2000-04-06 | Treatment of fungal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364396T1 true ATE364396T1 (de) | 2007-07-15 |
Family
ID=9889204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01911971T ATE364396T1 (de) | 2000-04-06 | 2001-03-20 | Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20030180285A1 (de) |
| EP (4) | EP1818062A3 (de) |
| JP (1) | JP2003530357A (de) |
| CN (3) | CN101683525A (de) |
| AT (1) | ATE364396T1 (de) |
| AU (2) | AU2001240890B2 (de) |
| BR (1) | BR0109846A (de) |
| CA (1) | CA2401836A1 (de) |
| CY (1) | CY1106794T1 (de) |
| DE (1) | DE60128893T2 (de) |
| DK (1) | DK1267925T3 (de) |
| ES (1) | ES2287105T3 (de) |
| GB (1) | GB0008305D0 (de) |
| NO (1) | NO20024815L (de) |
| NZ (1) | NZ520899A (de) |
| PL (1) | PL358394A1 (de) |
| PT (1) | PT1267925E (de) |
| RU (1) | RU2262952C2 (de) |
| WO (1) | WO2001076627A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| EP1457499A1 (de) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitoren des extrazellulären Hitzeschockproteins Hsp90 |
| US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| GB0409077D0 (en) | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
| NZ552508A (en) * | 2004-07-02 | 2009-10-30 | Neutec Pharma Ltd | Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies |
| KR20070050918A (ko) * | 2004-07-02 | 2007-05-16 | 뉴텍 파마 피엘씨 | 암의 치료 |
| EP2500031A3 (de) * | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Gefäßpermeabilität |
| KR101411167B1 (ko) * | 2005-04-13 | 2014-06-23 | 아스텍스 테라퓨틱스 리미티드 | 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도 |
| GB0600168D0 (en) * | 2006-01-05 | 2006-02-15 | Neutec Pharma Plc | A therapeutic composition |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
| WO2008116216A1 (en) * | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
| US20100113355A1 (en) * | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2008132174A1 (en) * | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
| US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
| CN111116743B (zh) * | 2018-10-30 | 2022-01-28 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
| CN111679069A (zh) * | 2019-12-31 | 2020-09-18 | 安徽中医药大学 | 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| US5834592A (en) * | 1995-09-22 | 1998-11-10 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6375955B1 (en) * | 1995-09-22 | 2002-04-23 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| US6365165B1 (en) * | 1995-09-22 | 2002-04-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2000
- 2000-04-06 GB GBGB0008305.5A patent/GB0008305D0/en not_active Ceased
-
2001
- 2001-03-20 DK DK01911971T patent/DK1267925T3/da active
- 2001-03-20 EP EP07075188A patent/EP1818062A3/de not_active Withdrawn
- 2001-03-20 ES ES01911971T patent/ES2287105T3/es not_active Expired - Lifetime
- 2001-03-20 PL PL01358394A patent/PL358394A1/xx not_active Application Discontinuation
- 2001-03-20 EP EP01911971A patent/EP1267925B8/de not_active Expired - Lifetime
- 2001-03-20 EP EP07075857A patent/EP2011512A1/de not_active Withdrawn
- 2001-03-20 JP JP2001574143A patent/JP2003530357A/ja active Pending
- 2001-03-20 NZ NZ520899A patent/NZ520899A/en not_active IP Right Cessation
- 2001-03-20 AU AU2001240890A patent/AU2001240890B2/en not_active Ceased
- 2001-03-20 EP EP07075462A patent/EP1852128A1/de not_active Withdrawn
- 2001-03-20 CN CN200910167220A patent/CN101683525A/zh active Pending
- 2001-03-20 DE DE60128893T patent/DE60128893T2/de not_active Expired - Lifetime
- 2001-03-20 AT AT01911971T patent/ATE364396T1/de active
- 2001-03-20 AU AU4089001A patent/AU4089001A/xx active Pending
- 2001-03-20 WO PCT/GB2001/001195 patent/WO2001076627A1/en not_active Ceased
- 2001-03-20 RU RU2002129510/15A patent/RU2262952C2/ru not_active IP Right Cessation
- 2001-03-20 CN CN01807383A patent/CN1420786A/zh active Pending
- 2001-03-20 BR BR0109846-2A patent/BR0109846A/pt not_active IP Right Cessation
- 2001-03-20 CN CNA2007101126651A patent/CN101095952A/zh active Pending
- 2001-03-20 US US10/240,819 patent/US20030180285A1/en not_active Abandoned
- 2001-03-20 PT PT01911971T patent/PT1267925E/pt unknown
- 2001-03-20 CA CA002401836A patent/CA2401836A1/en not_active Abandoned
-
2002
- 2002-10-04 NO NO20024815A patent/NO20024815L/no not_active Application Discontinuation
-
2007
- 2007-08-07 CY CY20071101053T patent/CY1106794T1/el unknown
- 2007-11-14 US US11/984,177 patent/US20100285029A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/076,643 patent/US20080193459A1/en not_active Abandoned
- 2008-03-21 US US12/076,705 patent/US20080181884A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE364396T1 (de) | Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern | |
| CY1119353T1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| ATE414106T1 (de) | Pegylierte single-domain-antikörper (dab) | |
| MX421450B (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19) | |
| CY1118053T1 (el) | Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea | |
| NO20030621D0 (no) | Anti-dual integrin antistoffer, sammensetninger, fremgangsmåter og anvendelser | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| EA200600275A1 (ru) | Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения | |
| DK2316852T3 (da) | Stabiliserede enkeltdomæne-antistoffer | |
| BRPI0406574A (pt) | Conjugados de anticorpo - antraciclina | |
| DK1257584T3 (da) | Humaniserede antistoffer, som sekvestrerer | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
| DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
| BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
| DE50015629D1 (de) | Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen | |
| DK1713830T3 (da) | Anti-epcam-immunglobuliner | |
| DK1684770T3 (da) | Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft | |
| TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
| DE60109359D1 (de) | Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten | |
| DK1534750T3 (da) | Terapeutisk brug af monoklonale antistoffer mod angiotensin-II type-1 receptoren | |
| ATE411056T1 (de) | Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1267925 Country of ref document: EP |